Baiya Phytopharm Co., Ltd.
Baiya Phytopharm is a clinical-stage biopharmaceutical company dedicated to strengthening health security for all people through innovative plant-based therapeutics and vaccines. Utilizing the BaiyaPharming™ platform, the company develops biologics such as monoclonal antibodies and vaccines, aiming to replace traditional biotech fermentation with scalable plant technology. Their mission is to address high unmet medical needs in the Asia-Pacific region by creating accessible, effective biopharmaceutical solutions.
Industries
Nr. of Employees
small (1-50)
Baiya Phytopharm Co., Ltd.
254 Chulapat 14 Building, 11st floor, Chulalongkorn University, Phayathai Road, Wang Mai, Pathum Wan, Bangkok, 10330
Products
Plant-produced basic fibroblast growth factor (bFGF)
Transiently expressed and purified basic fibroblast growth factor produced in Nicotiana benthamiana for use in cosmetic formulations and as a component of cell-culture media (including cultivated meat applications).
Plant-produced human epidermal growth factor (hEGF)
Transiently expressed and purified epidermal growth factor from Nicotiana benthamiana for cosmetic and cell-culture applications, supporting epidermal and fibroblast proliferation.
Plant-produced basic fibroblast growth factor (bFGF)
Transiently expressed and purified basic fibroblast growth factor produced in Nicotiana benthamiana for use in cosmetic formulations and as a component of cell-culture media (including cultivated meat applications).
Plant-produced human epidermal growth factor (hEGF)
Transiently expressed and purified epidermal growth factor from Nicotiana benthamiana for cosmetic and cell-culture applications, supporting epidermal and fibroblast proliferation.
Services
Pilot-to-GMP contract manufacturing covering upstream (bacterial culture, plant infiltration/extraction), downstream purification, and cell bank services.
Molecular cloning, small-scale protein expression and purification, and related R&D testing.
Supply of N. benthamiana plants and seeds, cultivation optimization, GAP consulting and seed bank establishment.
Protein and pharmaceutical-related testing including mass spectrometry, purity assays, endotoxin testing, ELISA potency tests, and method development/validation.
Regulatory affairs support, dossier preparation, supplier audits, gap analysis, pre-audit ISO9001/GMP review, and QMS documentation (SOPs, Site Master File, Quality Manual).
Provision and servicing of laboratory instruments and equipment to support R&D and manufacturing.
Pilot-to-GMP contract manufacturing covering upstream (bacterial culture, plant infiltration/extraction), downstream purification, and cell bank services.
Molecular cloning, small-scale protein expression and purification, and related R&D testing.
Supply of N. benthamiana plants and seeds, cultivation optimization, GAP consulting and seed bank establishment.
Protein and pharmaceutical-related testing including mass spectrometry, purity assays, endotoxin testing, ELISA potency tests, and method development/validation.
Regulatory affairs support, dossier preparation, supplier audits, gap analysis, pre-audit ISO9001/GMP review, and QMS documentation (SOPs, Site Master File, Quality Manual).
Provision and servicing of laboratory instruments and equipment to support R&D and manufacturing.
Expertise Areas
- Plant molecular farming
- Biologics manufacturing (GMP)
- Vaccine development and clinical testing
- Monoclonal antibody engineering
Key Technologies
- Transient expression in Nicotiana benthamiana
- Plant infiltration and extraction workflows
- Bacterial expression systems (upstream culture)
- LC-QTOF-MS (intact mass, peptide mapping)
News & Updates
Preliminary results show the vaccine is safe and trials should continue.
The company is developing a vaccine using tobacco leaves to fight COVID-19, aiming to make Thailand a vaccine producer.
Discussion on using tobacco leaves for vaccine development to combat emerging diseases.
First plant-derived COVID-19 vaccine entering human clinical trials in Asia
Baiya SARS-CoV-2 Vax 1 entered clinical trials in July 2021, marking a significant milestone in plant-based vaccine development.
Development of broad portfolio of biologic candidates
The company has generated a broad proprietary portfolio including monoclonal antibodies and vaccines for tropical diseases.
Preliminary results show the vaccine is safe and trials should continue.
The company is developing a vaccine using tobacco leaves to fight COVID-19, aiming to make Thailand a vaccine producer.
Discussion on using tobacco leaves for vaccine development to combat emerging diseases.
First plant-derived COVID-19 vaccine entering human clinical trials in Asia
Baiya SARS-CoV-2 Vax 1 entered clinical trials in July 2021, marking a significant milestone in plant-based vaccine development.
Development of broad portfolio of biologic candidates
The company has generated a broad proprietary portfolio including monoclonal antibodies and vaccines for tropical diseases.